Btg Share Discussion Threads

[gregmorg] 04/2/2016 11:37

close season update in April is the next scheduled announcement as I understand it

[fhmktg] 04/2/2016 11:19

Just re-read last year's IMS- the Company said that they would no longer issue these statements, so a little longer to wait for the Finals.

[fhmktg] 04/2/2016 00:38

That interim statement was Feb 5th last year.

[a1ord53] 03/2/2016 21:29

No updates or news on Varethena yet , any ideas if it is progressing or its now looks like a/the flop ?
Please, share your info , thanks all in advance.

[bargainbob] 03/2/2016 17:36

Worth a read

[fhmktg] 03/2/2016 15:19

What a travesty of an sp, after news like today's!

[bargainbob] 03/2/2016 12:32

Yes the Phillips link has mayor benefits.

[fhmktg] 03/2/2016 11:55

Hope for patients and credibility for BTG, well done team!

[bill hunt] 03/2/2016 10:14

New development with beads and Phillips.

[fhmktg] 01/2/2016 15:49

But a lot of selling by Norwich!

[fhmktg] 29/1/2016 14:01

More Norse buying!

[cyman] 27/1/2016 11:47

broker reiteration yet capitulation continues. it's been a mucky market since January opening with no change in sentiment on the horizon. perhaps mood might pick up a bit by end of day depending on what fed says about the recent interest rates change

[fhmktg] 26/1/2016 23:40

Great news on Therasphere approval in South Korea; three countries in Asia now approved and over 20000 patients treated worldwide.Roll on Taiwan and China!

[fhmktg] 22/1/2016 00:08

Not at this price- I suspect Mr W has greater ambition.Positive proof that each segment of the business is on its way towards the 2021 target, then an auction could get underway.2018 should see the share price above £10 imho to start the process for certain.

[bargainbob] 21/1/2016 17:23

He he , what are their plans.

[semper vigilans] 21/1/2016 06:37

Thanks Bookish.

[semper vigilans] 20/1/2016 15:06

Good write up on Vistogard but not listed here as an RNS yet

[a1ord53] 17/1/2016 09:27

this is from Capital Cube:

www.capitalcube.com/blog/index.php/btg-plc-neutral-assessment-on-price-but-strong-on-fundamentals/

[fhmktg] 13/1/2016 09:29

For a condition like emphysema,where there are so few treatments, this is excellent news for sufferers.Roll on with the fda submission and hopefully an expedited review process.

[bookish] 13/1/2016 08:28

BTG announces positive results from emphysema study BTG.L - DATMTR


13-JAN-2016 08:05:36

BTG plc, a specialist healthcare company, has announced the positive results from the RENEW study, an US randomised controlled clinical trial comparing the safety and efficacy of the PneumRx endobronchial coil implant, or EBCI, with a medical therapy control group in patients with homogeneous and/or heterogeneous severe emphysema.


All primary and secondary endpoints of the study were met. Patients treated with the PneumRx EBCI showed a statistically significant 10.2 metre benefit vs. control patients in change in the six minute walk test (6MWT) at 12 months, which was the study primary endpoint (p=0.0153).Importantly, patients treated with the PneumRx EBCI exhibited statistically significant and clinically meaningful improvements vs. control patients at 12 months in Quality of Life measured by Saint George Respiratory Questionnaire (SGRQ) (mean improvement of 8.9 points over the control group, p < 0.0001) and lung function measured by Forced Expiratory Volume in one second (FEV1) (mean litres percent improvement of 8.8% over the control group, p < 0.0001).Serious adverse events in the treatment and control groups were as expected in a patient population of mostly GOLD IV patients. Events associated with bronchoscopy and EBCI placement such as pneumothorax, lower respiratory tract infections, respiratory failure, haemoptysis, COPD exacerbation, and dyspnoea occurred, as anticipated, at a higher rate in the treatment arm.

Louise Makin, BTG's CEO, commented: "We are delighted with the successful outcome of RENEW, showing significant benefit in patients treated with the PneumRx Coils in one of the largest randomised controlled clinical trials of a medical device in patients with severe emphysema to date incorporating both patient reported and objective outcomes.
We will now progress our regulatory application in the US, which we anticipate submitting around mid-2016."RENEW included 315 patients who were randomised to receive treatment with the PneumRx EBCI or standard of care medical therapy. The primary endpoint of the study was a mean absolute improvement from baseline at 12 months in the 6MWT. The secondary endpoints included a 6MWT responder analysis, FEV1 mean percent change measured using spirometry and SGRQ mean absolute difference. Detailed analysis of the data continues, with full data expected to be submitted to a peer-reviewed journal for publication in due course.The PneumRx Endobronchial Coil Implant (EBCI) is a shape-memory nitinol coil implanted in the sub-segmental airways of the lung in patients with severe emphysema via a minimally invasive bronchoscopic procedure.